Pharmacokinetic Properties of Anisoylated Plasminogen Streptokinase Activator Complex and Other Thrombolytic Agents in Animals and in Humans
- 1 January 1987
- journal article
- Published by Springer Nature in Drugs
- Vol. 33 (Supplement) , 88-92
- https://doi.org/10.2165/00003495-198700333-00013
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Die Bolusinjektion von anisoyliertem Plasminogen-Streptokinase-Aktivator-Komplex (BRL 26921) als alternatives Konzept der systemischen Lyse bei akutem MyokardinfarktJournal of Molecular Medicine, 1986
- High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: Description of effects in the circulationThe American Journal of Cardiology, 1986
- Thrombolytic therapy in the eighties.1986
- Clinical effects and kinetic properties of intravenous APSAC — anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarctionInternational Journal of Cardiology, 1986
- Coronary Thrombolysis with Human Single-Chain, Urokinase-Type Plasminogen Activator (Pro-Urokinase) in Patients with Acute Myocardial InfarctionAnnals of Internal Medicine, 1986
- Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1985
- Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in RabbitsThrombosis and Haemostasis, 1981
- DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT . MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION1965